Schematic outline showing Snrnp200 -targeted ASO treatment or LDH inhibition combined with anti-PD-1 antibody treatment of tumors: 5 x 10 5 4T1 mouse breast cancer cells were subcutaneously injected into BALB/c mice. When the tumors reached 50–100 mm 3 , the mice were treated with ASO- Snrnp200 (5 mg/kg subcutaneous injection, twice a week, n = 6 mice/group), FX-11 (2 mg/kg daily i.p. injection, daily), or PBS (50 uL, i.p. injection, daily) for 2 weeks combined with an isotype control or anti-PD-1 antibody (10 mg/kg, i.p. injection, twice a week).
